{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":1320,"summary":"Hosted by Corey with the Story. Stay informed with the latest business, stock market, and finance headlines, updates, and breaking stories delivered daily in quick, engaging episodes. Subscribe! The Daily News Now! — Every city. Every story. AI-powered. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-06-17T18:18:57.837082+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"CRISPR’s Hidden Value Amid Stock Dip","slug":"crispr-s-hidden-value-amid-stock-dip","published_at":"2026-06-08T18:06:27+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/crispr-s-hidden-value-amid-stock-dip","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://api.fastcast.ai/audio/2e3af031-a26d-4ab1-986c-4666890c99ed.mp3","audio_url":"https://api.fastcast.ai/audio/2e3af031-a26d-4ab1-986c-4666890c99ed.mp3","summary":"CRISPR Therapeutics holds a blockbuster gene-editing therapy, Casgevy, approved for blood disorders and already treating 500+ patients at a $2.2M price tag—yet its stock trades 40% below analyst estimates. Despite Nobel-winning tech and a pipeline targeting diabetes, heart disease, and more, investors hesitate due to high costs, delayed revenue recognition, and profit-sharing with Vertex. A recent $600M raise risks dilution, but the long-term upside is massive: analysts see a much higher price target, and the company remains a prime acquisition target as the gene-editing field surges. It’s a high-risk, high-reward biotech bet—waiting for the market to believe the science will soon pay off. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/d36ccb29d00f5984","meta_description":"CRISPR Therapeutics holds a blockbuster gene-editing therapy, Casgevy, approved for blood disorders and already treating 500+ patients at a $2.2M price ta…","key_points":[],"chapters":[],"topics":[],"duration_seconds":141,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/crispr-s-hidden-value-amid-stock-dip/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/crispr-s-hidden-value-amid-stock-dip.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}